Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Molecular and Cellular Biochemistry|May 29, 2025
Ferroptosis in TNBC: interplay with tumor-infiltrating immune cells and therapeutic implicationsLihong Hu, Jiejie Hu, Chengdong Qin, et al.Frontiers in Medicine|January 23, 2025
The potential benefits of radiotherapy in elderly patients with early-stage triple-negative breast cancerZheng Xu, Chengdong Qin, Binxiao Cao, et al.Postgraduate Medical Journal|May 6, 2025
Roles of macrophages and monocytes in resistance to immunotherapy in breast cancersSiyuan Liu, Lihong Hu, Jiejie Hu, et al.Frontiers in Pharmacology|June 16, 2023
Tanshinone IIA promotes vascular normalization and boosts Sorafenib's anti-hepatoma activity via modulating the PI3K-AKT pathwayChengdong Qin, Siyuan Liu, Shiqi Zhou, et al.Journal of Cancer Research and Clinical Oncology|March 2, 2019
Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteinsNing Zhang, Hui Li, Chengdong Qin, et al.Journal of Translational Medicine|July 14, 2026
HOXD10 promotes hepatocellular carcinoma progression by enhancing m6A methylation and activating the PI3K/AKT/mTOR pathwayChengdong Qin, Xinyi Gao, Siyuan Liu, et al.Cancer Biology & Therapy|May 19, 2020
The treatment option of progressive disease in breast cancer during neoadjuvant chemotherapy: a single-center experienceYurong Zheng, Xiaowen Ding, Dehong Zou, et al.Cancer Management and Research|December 16, 2024
Oncoplastic Breast-Conserving Surgery for Upper Inner Quadrant Breast Cancer Using Pedicled Pectoralis Major Myofascial FlapJie Jie Hu, Chengdong Qin, Siyuan Liu, et al.Frontiers in Immunology|April 17, 2023
PIK3C2A is a prognostic biomarker that is linked to immune infiltrates in kidney renal clear cell carcinomaChengdong Qin, Siyuan Liu, Shiqi Zhou, et al.Oncology Research and Treatment|June 11, 2023
Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialYuqin Ding, Wenju Mo, Xiaohong Xie, et al.Pageof 2